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Summary
Background Because survival benefits of treatment with
radiotherapy are questionable and such treatment can
cause substantial damage to the brain over time, the
optimum management strategy for low-grade gliomas
remains controversial. We aimed to identify the specific
effects of radiotherapy on objective and self-reported
cognitive function, and on cognitive deterioration over time,
in patients with low-grade gliomas treated with early
radiotherapy.
Methods 195 patients with low-grade glioma (of whom 104
had received radiotherapy 1–22 years previously) were
compared with 100 low-grade haematological patients and
195 healthy controls. Our analyses aimed to differentiate
between the effects of the tumour (eg, disease duration,
lateralisation) and treatment effects (neurosurgery,
radiotherapy, antiepileptic drugs) on cognitive function and
on relative risk of cognitive disability. 
Findings Low-grade glioma patients had lower ability in all
cognitive domains than did low-grade haematological
patients, and did even less well by comparison with healthy
controls. Use of radiotherapy was associated with poorer
cognitive function; however, cognitive disability in the
memory domain was found only in radiotherapy patients
who received fraction doses exceeding 2 Gy. Antiepileptic
drug use was strongly associated with disability in
attentional and executive function.
Interpretation Our findings suggest that the tumour itself
has the most deleterious effect on cognitive function and
that radiotherapy mainly results in additional long-term
cognitive disability when high fraction doses are used.
Additionally, the effects of other medical factors, especially
antiepileptic drug use, on cognitive function in glioma
patients deserve attention. 
Lancet 2002; 360: 1361–68 
Introduction
Among adult cancer patients, patients with gliomas (ie,
primary brain tumours arising from glial tissue) form a
minority. Compared with lung and breast cancer, which
have rates of about 60 per 100 000 in the Netherlands,
the rate of gliomas is tenfold lower, with about 1000 new
patients every year.1 Nevertheless, these cancers have a
serious effect on the health-care system in general, and
especially on patients and their families. Not only do
glioma patients have to cope with the diagnosis of
incurable disease, they and their families are usually also
confronted with the patient’s decrease in cognitive and
emotional function as a result of cerebral disease. 
Although the median survival of adult glioma patients
with low-grade tumours is much longer than that of
those with high-grade tumours, nearly all will die of their
disease. In these patients, early treatment does not
prolong survival,2 and no randomised prospective studies
have been done to assess the effects of neurosurgery.
Moreover, retrospective data on the role of neurosurgery
in extended survival (as opposed to a policy of
observation) are controversial.3
What is the role of early radiotherapy in these
patients? Low-grade gliomas can be moderately
responsive to radiotherapy,4 but the survival benefits of
adjuvant radiotherapy after neurosurgery are debatable.
Results of some retrospective studies suggest that early
radiotherapy improves survival;5 other investigators have
reported that it does not,6 or have shown that older
patients might benefit most.5 Findings of several studies
by the European Organisation for the Research and
Treatment of Cancer (EORTC) clearly do not
recommend early treatment with radiotherapy of
patients with low-grade gliomas.7,8
Apart from potential favourable survival effects,
radiotherapy itself could negatively affect the patient’s
health-related quality of life through irreversible 
late-delayed brain damage induced by irradiation,
ultimately resulting in cognitive deficits and dementia.9,10
In long-term survivors of brain metastases from 
systemic cancer, and in patients with primary lymphoma
of the central nervous system, treatment with 
whole-brain radiotherapy can lead to radiation-induced
encephalopathy.11,12 Partly because of these side-effects,
standard treatment of glioma patients is based on focal
radiotherapy rather than on whole-brain radiotherapy.
Apart from a large radiotherapy treatment volume, high
radiotherapy total and fraction dose, concomitant
chemotherapy, and old age have been identified as
potential risk factors for cognitive deterioration in glioma
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acknowledgments section). Between these centres,
therapeutic policies differed as to the use of early
radiotherapy for low-grade glioma. Irradiated patients
were recruited from centres at which early radiotherapy
for low-grade glioma was favoured. The study protocol
was approved by the medical ethics committees of the
institutions.
Eligibility was checked with the general practitioner
and by case-note review. Because study resources were
restricted, we aimed to include a maximum of 200 low-
grade glioma patients and 100 patients with low-grade
haematological cancers stratified geographically (three
regions), by disease duration (1·0–3·5 years,
3·6–6·0 years, or 6·1 years or longer) and, for low-grade
glioma patients, having received radiotherapy
(LGG/RT+) or not (LGG/RT). We classified low-
grade glioma histologically as astrocytomas, oligodendro-
gliomas, or oligoastrocytomas. Low-grade haematological
cancers were restricted to non-Hodgkin lymphomas or
chronic lymphatic leukaemia (NHL/CLL) without
clinical signs of central nervous system involvement.
Patients with NHL/CLL were recruited to compare the
cognitive outcome of glioma patients with the
psychological effect of having cancer per se on cognitive
function.17
Tumour recurrence or progression for both low-grade
glioma and NHL/CLL patients usually arises after a
period of stable disease, and survival rates are similar.
Moreover, there are similarities between these tumours
with regard to their development and biological
behaviour. LGG/RT+ patients were only included if they
received radiotherapy as primary treatment within
2 months of histological diagnosis. Patients were
excluded if they used corticosteroids, did not have a basic
proficiency in the Dutch language, or were unable to
communicate adequately.
In addition to glioma and NHL/CLL patients,
normative data from a cohort of healthy controls were
included in this study. These data were taken from the
Maastricht Aging Study18 which comprised several
studies of the biomedical and psychological determinants
of cognitive ageing. The core project was a large cross-
sectional study of 2000 healthy individuals aged
24–81 years who were followed up for 12 years with
regard to health characteristics and neurocognitive status.
Healthy controls were individually matched with low-
grade glioma patients for age, sex, and educational level,
since these sociodemographic characteristics are known
to affect cognitive functioning. The latter variable was
assessed by a Dutch scoring system that consists of an
8-point scale, ranging from unfinished primary education
(level 1) to university education (level 8). 
The treating physician invited the patients by letter to
participate in the study. Informed consent procedures
preceded patients’ agreement to participate. Before the
day of formal testing, patients completed a postal
questionnaire about sociodemographic data, including
age, sex, and educational level. During testing we
obtained clinical data for functional status, cognitive
assessment, and self-reported health-related quality of
life; the latter will be the subject of a separate paper.
Patients could choose to be tested at home or in the
treating hospital.
Clinical data obtained at entry included tumour
characteristics (histology, site) and treatment history
(neurosurgery, biopsy vs resection; radiotherapy target,
focal vs whole-brain; radiotherapy total dose and fraction
dose; boost; and antiepileptic drugs). All clinical data
were taken from the case-note reviews.
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patients.9 The incidence of late-delayed encephalopathy
in these patients is steadily increasing, not only because
of increased survival but also because of improved
detection (neuroimaging and extensive cognitive function
testing) and raised awareness among physicians and
patients.9
With 5-year and 10-year progression-free rates of 50%
and 12%, respectively, for supratentorial low-grade
astrocytomas, low-grade oligodendrogliomas, and mixed
gliomas,13 and a median better survival of 16·7 years for
the latter two groups,14 patients with low-grade gliomas
can survive in a stable state for several years after
diagnosis. The long-term cognitive and psychosocial
sequelae of the disease and its treatment in these long-
term survivors are especially salient. In 1994, we showed
serious cognitive deficits in low-grade glioma patients,
which, surprisingly, could not be attributed to focal
radiotherapy.15 Here, we present results from a
nationwide study with a larger group of such patients and
with the use of a more extensive cognitive test battery
than in our previous report. 
We aimed to delineate changes in cognitive function
and cognitive disability as defined by the WHO
International Classification of Functioning, Disability
and Health (ICIDH-2).16 ICIDH-2 components of
function and disability can be expressed in two ways.
They can be used to indicate non-problematic aspects of
health and health-related states, summarised under the
umbrella term functioning; or they can indicate problems
(eg, impairment, activity limitation, or participation
restriction), summarised under the umbrella term
disability. 
In line with our previous research, we aimed to
establish the effect of the tumour (ie, duration of disease,
tumour lateralisation) and of treatment (ie, neurosurgery,
radiotherapy, antiepileptic drugs) on the mid-to-long-
term cognitive function of patients with low-grade
glioma. Since we postulated that reductions in cognitive
function caused by radiation therapy increase over time,
the long-term effect of radiotherapy received special
attention. Furthermore, we aimed to find out whether,
because the central nervous system is implicated, brain-
tumour patients have more extensive cognitive deficits
than patients with cancer outside the brain. Cognitive
function in patients with non-brain tumours is thought to
be compromised by the psychological effect of cancer.
Additionally, we tested the hypothesis that especially in
brain-tumour patients, there is a dissociation between
subjective cognitive complaints and observed cognitive
functioning. 
With the ICIDH-2 classification in mind, we first
defined the extent of restrictions in cognitive function in
glioma patients by comparison with patient controls and
with healthy controls, and by identification of tumour
and treatment characteristics related to cognitive
functioning. Subsequently, we investigated which
tumour-related and treatment-related characteristics
were associated with increased risk of cognitive disability. 
Methods
Patients and methods
In this multicentre study, we recruited low-grade glioma
patients and patients with low-grade haematological
cancers who had (a) no clinical signs of tumour
recurrence for at least 1 year after the histological
diagnosis and primary treatment, and (b) no radiological
signs of recurrence within 3 months before testing.
Patients were recruited from neurosurgical centres
throughout the Netherlands (listed in the
For personal use. Only reproduce with permission from The Lancet Publishing Group.
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Study measures
We assessed patients’ overall degree of physical function
with the Karnofsky performance status scale,19 which is
frequently used in clinical oncological research. Scores
range from 0 (lowest level) to 100 (highest level).
The ability to do daily activities was assessed with the
Barthel activities of daily living index.20 This index consists
of ten items (assessing continence of bowels and bladder,
grooming, toilet use, feeding, transfer, mobility, dressing,
climbing stairs, and bathing) which are ordered in
ascending degree of difficulty. High scores indicate good
functional independence.
We rated neurological functioning with the neurological
functional status scale developed by Order and
colleagues.21 Originally developed for use with patients
with brain metastases, this scale has been used in studies
with brain-tumour patients. Scores range from 1 to 4, with
high scores for strong neurological function.
Cognition refers to an individual’s ability to perceive,
store, retrieve, and use sensory and perceptual information
from the environment and past experience, and to such
mental activities as plans and strategies. Detailed
information about the standard tests used to assess
cognitive status is shown in the panel. Because of the
heterogeneity in the origin and severity of cognitive
disturbances in patients with glioma, we assessed a wide
range of functions. Since inspection of the performance
patterns of individual patients can be very useful, because
it could reveal information that is not apparent from
analyses of the group means, we calculated a disability
score for every patient; cognitive test scores were converted
to z scores, with the mean scores of the healthy controls as
a reference. We defined cognitive disability as a test score
of 2 SD below the mean of the healthy controls. To
calculate an overall disability score for every patient, we
counted the number of tests on which the patient was
disabled. The 95th percentile of the healthy controls was
used as a cutoff score for cognitive disability.25 The
application of this algorithm to our data showed that a
glioma patient was judged to have a cognitive disability if
he or she had deviant scores for at least four of the 20 tests.
Only tests for which healthy controls could be individually
matched with low-grade glioma patients for age, sex, and
educational level were used for this analysis.
We assessed self-reported cognitive function with a six-
item scale developed for use in the Medical Outcomes
Study.26 This scale assesses day-to-day problems with
cognitive function, such as difficulty with reasoning and
problem solving, slowed reaction time, forgetfulness, and
problems with concentration. Raw scores are converted
linearly to a 0–100 scale, with high scores for high levels of
self-reported cognitive function.
Statistical analysis
We did analysis of covariance (F tests), with correction for
differences in age, sex, education, and disease duration, to
test for differences between glioma and NHL/CLL patient
groups in mean scores for objective cognitive functioning.
Additional Student’s t tests for independent samples were
done to determine whether cognitive function of glioma
patients differed from that of healthy controls. Because of
the exploratory nature of this analysis, no correction for
multiple comparisons was applied. We investigated the
prevalence of cognitive disability (on the basis of previously
described cutoff scores) in glioma versus NHL/CLL, and
in irradiated versus non-irradiated glioma patients, with
logistic regression analysis, corrected for differences in age,
sex, education, and duration of disease. Disease duration
for both glioma and NHL/CLL patients was defined as the
time between histological diagnosis and formal
neuropsychological testing.
To assess the association between objective and self-
reported cognitive function in glioma patients, we
calculated Pearson’s correlations between functional
indicators of four major cognitive domains: memory
(visual verbal learning test total recall), attention (Stroop
colour-word test-III), psychomotor speed (letter-digit
substitution test-writing), and graphomotor speed
(concept-shifting test motor), and the Medical Outcomes
Study scale. For purposes of data reduction, we chose
these outcome measures since they correlate well with
other tests in the same cognitive domain and thus are
judged to be representative for this domain.
To identify which tumour-related and treatment-related
characteristics were associated with objective and self-
reported cognitive functioning, we did a stepwise linear
regression analysis with possible confounders (ie, age, sex,
and education) entered into the model at the first step.
Subsequently, duration of disease, use of radiotherapy,
relation between radiotherapy and disease duration
(entered as an interaction term), antiepileptic drug use
(none vs any), tumour lateralisation (left vs right), and
neurosurgical intervention (biopsy vs resection) were
entered as independent variables. The separate cognitive
test scores, the Medical Outcomes Study scale, and the
total number of deviant test scores based on a cutoff of 
Neuropsychological domains and specific tests used in the study
Intelligence
Dutch adult reading test22 Estimates premorbid intellectual functioning on the basis of verbal ability
Perception and psychomotor speed
Line bisection test23 Measures unilateral neglect, which is usually a sequel of massive right hemisphere lesions
Facial recognition test23 Detects impairment in the discrimination of faces, a disorder associated with right 
hemisphere lesions
Judgment of line orientation test23 A test of visuospatial judgment, also detects right hemisphere dysfunction
Letter-digit substitution test (LDST)23 Measures psychomotor speed that is relatively unaffected by a decline in intellectual ability
Memory
Visual verbal learning test (VVLT)23 Examines several aspects of verbal learning, organisation, and memory
Working memory task (WMT)23 Measures the speed of memory processes
Attention and executive function
Stroop colour-word test (SCWT)23 Examines attention, mental speed, and mental control
Categoric word fluency task23 Measures the speed and flexibility of verbal thought processes
Concept shifting test (CST)24 Measures attention, visual searching, mental-processing speed, and the ability to mentally 
control simultaneous stimulus patterns
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Results
195 adult patients with supratentorial low-grade gliomas
were recruited between February, 1997, and January,
2000, of whom 104 (53%) had received radiotherapy
1–22 years previously. Focal radiotherapy, with a margin
of 2 cm around the lesion seen by CT or MRI, was
mostly used. In several centres, a boost radiation dose,
limited to the tumour volume, was given alongside focal
radiotherapy. About 10% of patients had whole-brain
radiotherapy, with or without boost. The main reason
for whole-brain radiotherapy was a large tumour volume
that made focal radiation very difficult. Low-grade
glioma patients were compared with 100 patients with
low-grade NHL/CLL. 44 of the 239 glioma patients
(18%) and 38 of the 138 NHL/CLL patients (28%) who
met the inclusion criteria declined to participate; the
main reasons given were that patients found
participation too burdensome, or were reluctant to be
confronted with what they believed to be a cured illness.
93% of glioma patients and 96% of NHL/CLL patients
were tested at home; the rest were tested in the hospital. 
Table 1 shows the sociodemographic and clinical
characteristics of the LGG/RT, LGG/RT, and
NHL/CLL patient groups. NHL/CLL patients were
significantly older than the combined glioma group.
LGG/RT patients were older than LGG/RT patients
and had more frequently undergone biopsy. Disease
duration was longer in LGG/RT patients than in those
who were LGG/RT, but the disease duration of the
combined LGG/RT and LGG/RT group was shorter
than that of the NHL/CLL patients. The near optimum
levels of physical (Karnofsky scale) and neurological
functioning (Order scale) did not differ significantly
between the combined glioma group and NHL/CLL
patients, although glioma patients were more limited in
their activities of daily living (Barthel index). Although
LGG/RT and LGG/RT patients both attained high
levels of activities of daily living and neurological
functioning, the LGG/RT group had significantly
lower scores.
Data for cognitive function in glioma patients,
NHL/CLL patients, and healthy controls are shown in
table 2. After we corrected for differences in age, sex,
education, and disease duration, glioma patients scored
less well on tests of perception and psychomotor speed,
memory tests, and tests measuring attention and
executive function than did NHL/CLL patients.
Reductions in cognitive function were even more
pronounced when glioma patients were compared with
healthy matched controls. Univariate F tests for
LGG/RT patients versus LGG/RT patients showed
that irradiated patients scored poorly on one of seven
tests in the domain of perception and psychomotor
speed, on one of eight memory tests, and on one of 11
tests of attention and executive function (data not
shown). 
The glioma patients had much lower levels of 
self-reported cognitive functioning as assessed by 
the Medical Outcomes Study scales than did the 
healthy controls: 47·80 versus 82·40, respectively. For
the glioma group as a whole, objectively assessed
memory, attention, psychomotor speed, and grapho-
motor speed correlated moderately with self-reported
cognitive functioning (r=0·23, 0·30, 0·34, and 0·31,
respectively).
The proportion of patients with cognitive disability (as
defined in the methods) was significantly higher in the
glioma group as a whole than in the NHL/CLL patients
(66 [34%] vs 22 [22%], respectively; p=0·035, corrected
ARTICLES
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2 SD below the mean of the healthy controls were entered
as the dependent variables. In a subsequent identical
analysis restricted to the LGG/RT+ group, we calculated
the relative contributions of total radiotherapy dose and
fraction dose. The level of significance was set at p<0·05.
To identify tumour-related and treatment-related
factors that were associated not only with cognitive
functioning per se (ie, mean test scores), but also with
cognitive disability, we did an additional series of logistic
regression analyses. Using individual cognitive disability
scores (on the basis of the previously described cutoff of
2 SD below the mean of the healthy controls and
subsequent 5th percentile scores, which we assumed
would seriously interfere with everyday life functioning),
we calculated the relative risk and 95% CI for cognitive
disability, corrected for differences in age, sex, and
education, for the same variables as those used in the linear
regression analysis. Probability for entry was set at 0·05
and probability for removal at 0·10. 
Role of the funding source 
The sponsors of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report.
Patient groups
LGG/RT LGG/RT NHL/CLL p* p†
(n=104) (n=91) (n=100)
Characteristics
Mean age in years 42·6 (12·2) 38·7 (11·5) 49·7 (8·0) 0·017<0·0001
(SD)
Male sex 62 (59·6%) 58 (63·7%) 51 (51·0%) 0·555 0·083
Level of education‡ 4·1 (0·2) 4·2 (0·2) 4·2 (20·0) 0·782 0·491
(SD)
Premorbid intelligence
Dutch adult reading 99·9 (12·2) 100·0 (10·5) 102·4 (11·0) 0·936 0·072
test‡ (SD) 
Histological diagnosis 0·896
Astrocytoma 73 (70·2%) 66 (72·5%) ·· ··
Oligodendroglioma 24 (23·1%) 19 (20·9%) ·· ··
Oligoastrocytoma 7 (6·7%) 6 (6·6%) ·· ··
Low-grade NHL ·· ·· 71 (71·0%) ·· ··
CLL ·· ·· 29 (29·0%) ·· ··
Tumor lateralisation 0·125 ··
Left-sided 55 (52·9%) 42 (46·2%) ·· ··
Right-sided 43 (41·3%) 48 (52·7%) ·· ··
Bilateral 6 (5·8%) 1 (1·1%) ·· ··
Neurosurgical 
intervention <0·0001
Biopsy 55 (52·9%) 29 (31·9%) ·· ··
Resection 49 (47·1%) 62 (68·1%) ·· ··
Radiotherapy
Focal/+ boost 50 (48·1%)/ ·· ·· ··
44 (42·3%) 
Whole brain/+ boost 2 (1·9%)/ ·· ·· ·· ··
8 (7·7%)
Total dose Gy (SD) 55·6 (6·1) ·· ·· ·· ··
Fraction dose Gy (SD) 2·0 (0·1) ·· ·· ·· ··
Fraction dose 1·8–2 Gy 86 (82·7%) ·· ·· ·· ··
Fraction dose >2 Gy 18 (17·3%) ·· ·· ·· ··
Epileptic seizures 89 (85·6%) 78 (85·7%) ·· 0·933 ··
Antiepileptic drug use 74 (71·2%) 65 (71·4%) ·· 0·935 ··
Years since diagnosis 6·1 (4·1) 5·1 (2·9) 6·6 (4·0) 0·040 0·042
(SD)
Functional/
performance status
Karnofsky‡ (SD) 87·0 (16·3) 89·4 (10·5) 88·9 (11·0) 0·212 0·594
Barthel‡ (SD) 19·5 (2·0) 19·9 (1·0) 19·9 (1·0) 0·027 0·018
Order‡ (SD) 3·8 (1·0) 4·0 (1·0) 3·9 (1·0) 0·010 0·376
Data are number (%) of patients unless otherwise indicated. *Comparisons between
LGG/RT and LGG/RT groups, and †between combined glioma patients and
NHL/CLL patients. ‡Mean test scores (see text). 
Table 1: Sociodemographic and clinical characteristics of the study
patients
For personal use. Only reproduce with permission from The Lancet Publishing Group.
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for differences in age, sex, education, and disease
duration). Although more irradiated glioma patients had
deficient test scores than did non-irradiated glioma
patients (41 [39%] vs 26 [29%], respectively) these
differences were not significant (p=0·145). A reanalysis
of the data with exclusion of patients who received
whole-brain radiotherapy yielded similar results (35
[37%] vs 26 [29%], respectively; p=0·168). 
Linear regression analysis based on mean test scores
showed that the use of radiotherapy was associated with
poor scores on one of seven tests in the domain of
perception and psychomotor speed, and on two of eight
memory tests. Disease duration and objective cognitive
functioning were not related in glioma patients, although
the interaction between radiotherapy use and disease
duration suggested that cognitive functioning in
irradiated patients, but not in non-irradiated patients,
tends to fall over time. Evidence for this notion was
shown by scores of one of seven tests in the domain of
perception and psychomotor speed, two of eight memory
test scores, and three of 11 tests of attention and
executive function (data not shown). 
All glioma patients (n=152)† Radiotherapy patients only (n=82)†
Years since diagnosis Antiepileptics Tumour lateralisation
fraction dose (Gy)
Perception and psychomotor speed
LDST reading (nc) ·· ·· 2·25 (1·01–5·01)‡ ··
LDST motor component (nc) ·· 6·48 (1·14–36·89) ·· ··
Memory
VVLT max score (nc) ·· ·· ·· 6·23 (1·13–35·36) 
Delta score (nc) ·· ·· 15·83 (2·56–98·00) 
Total recall (nc) ·· ·· ·· 6·23 (0·96–40·33)
Delayed recall (nc) ·· ·· ·· 9·80 (1·22–78·72) 
Delayed recognition (nc) ·· ·· ·· 6·48 (0·95–44·10) 
Attention and executive function
SCWT card I (s) ·· ·· 2·54 (1·13–5·69)§ ··
SCWT card II (s) ·· ·· 2·29 (1·10–4·81)§ ··
SCWT card III (s) ·· 5·79 (2·40–13·95) 5·30 (2·24–12·56)§ ··
SCWT interference (%) ·· ·· 35·34 (4·16–300·01)§ ··
Fluency (nc) 1·20 (1·04–1·38) ·· ·· ··
CST A (s) 1·14 (1·02–1·29) 0·31 (0·10–0·96) ·· ··
CST C (s) ·· 0·30 (0·09–0·95) ·· ··
Only significant relations between neuropsychological parameters and tumour or treatment characteristics are listed. *Adjusted for age, sex, and education. †Due to
the listwise exclusion of missing values and exclusion of patients with midline gliomas, the number of patients in the regression analyses differs from that in the
univariate analyses summarised in table 2. Because of the exploratory nature of the study, the randomly missing values were not substituted by the overall mean,
subgroup means, or a regression estimate. ‡Patients with a tumour in the right hemisphere had more deficits in perceptual functioning. §Patients with a tumour in the
left hemisphere had more deficits in attentional functioning. See panel for definitions of test names.  
Table 3: Relative risk* (95% CI) of cognitive deficits according to tumour and treatment characteristics
Glioma patients (n=195) NHL/CLL patients (n=100) p* Healthy controls (n=195) p†
Perception and psychomotor speed
Line bisection-HD (cm)‡ 0·44 (0·15) –0·03 (0·21) 0·074 n/a (n/a) n/a
Line bisection-VD (cm)‡ 0·02 (0·16) –0·80 (0·23) 0·006 n/a (n/a) n/a
Facial recognition (nc)§ 21·55 (0·19) 22·40 (0·27) 0·015 n/a (n/a) n/a
Line orientation (nc)§ 12·71 (0·22) 12·21 (0·32) 0·223 n/a (n/a) n/a
LDST writing (nc)§ 42·55 (0·74) 50·21 (1·06) <0·0001 54·77 (0·69) <0·0001
LDST reading (nc)§ 49·53 (0·81) 57·70 (1·17) <0·0001 62·36 (0·72) <0·0001
LDST motor component (nc)§ 6·98 (0·39) 7·43 (0·56) 0·526 7·60 (0·32) 0·463
Memory
VVLT trial 1 (nc)§ 5·20 (0·14) 5·89 (0·21) 0·009 5·25 (0·12) 0·655
VVLT max score (nc)§ 10·98 (0·18) 11·93 (0·26) 0·004 12·13 (0·14) <0·0001
VVLT delta score (nc)§ 5·78 (0·16) 6·04 (0·23) 0·338 6·88 (0·14) <0·0001
VVLT total recall (nc)§ 42·11 (0·78) 47·18 (1·12) <0·0001 46·26 (0·61) 0·003
VVLT delayed recall (nc)§ 8·63 (0·23) 10·45 (0·33) <0·0001 9·96 (0·20) 0·001
VVLT delayed recognition (nc)§ 14·10 (0·11) 14·70 (0·15) 0·002 14·46 (0·07) 0·072
WMT slope‡ 17·21 (0·66) 13·62 (0·93) 0·003 13·13 (0·44) <0·0001
WMT intercept‡ 31·74 (0·84) 27·39 (1·19) 0·004 22·10 (0·39) <0·0001
Attention and executive function
SCWT card I (s)‡ 53·39 (1·05) 46·46 (1·51) <0·0001 43·63 (0·52) <0·0001
SCWT card II (s)‡ 70·71 (1·37) 59·02 (1·97) <0·0001 55·24 (0·66) <0·0001
SCWT card III (s)‡ 120·22 (3·28) 90·96 (4·70) <0·0001 85·95 (1·27) <0·0001
SCWT card IV (s)‡ 150·94 (5·99) 108·61 (8·51) <0·0001 n/a (n/a) n/a
SCWT interference (%)‡ 92·13 (3·79) 77·35 (5·43) 0·033 74·20 (1·87) 0·002
SCWT slowing (s)‡ 35·45 (5·18) 17·84 (7·34) 0·061 n/a (n/a) n/a
Fluency (nc)§ 20·60 (0·44) 24·17 (0·63) <0·0001 24·77 (0·41) <0·0001
CST A (s)‡ 27·15 (1·21) 21·07 (1·75) 0·006 17·69 (0·31) <0·0001
CST B (s)‡ 33·38 (2·10) 23·98 (3·08) 0·015 21·81 (0·44) <0·0001
CST C (s)‡ 43·49 (1·73) 33·94 (2·53) 0·003 27·51 (0·65) <0·0001
CST motor component (s)‡ 7·77 (0·31) 6·48 (0·44) 0·022 4·66 (0·06) <0·0001
Self-reported cognition§ 47·80 (1·61) 52·20 (1·71) 0·552 82·40¶ (1·66) <0·0001
cm=centimetres. nc=number correct. s=seconds. Means (SE) for glioma and NHL/CLL patients represent estimated means based on corrections for age, sex,
education, and disease duration. Means and SE for healthy controls are observed scores. See panel for explanation of abbreviations of test variables. n/a=Individually
matched data not available. *p values of univariate t tests for low-grade glioma patients vs NHL/CLL patients corrected for age, sex, and educational differences. 
†p values of t test comparisons between glioma patients and healthy age-, sex-, and education-matched controls. ‡Lower scores indicate  better performance. §Higher
scores indicate better performance. ¶Comparison based on historical controls. 
Table 2: Neuropsychological test scores of low-grade glioma patients, NHL/CLL patients, and healthy controls
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moreover, that these deficiencies are not restricted to a
single cognitive domain. Disturbances of cognitive
function in glioma patients are even more pronounced
when compared with matched healthy controls.
These results are in accord with our previous work,
which showed that the tumour itself, rather than
irradiation, adversely affects neurobehavioural function
in patients with low-grade glioma.15 However, we have
now additionally shown several differences in mean
cognitive function scores between low-grade glioma
patients who received radiotherapy and those who did
not. These differences might, in part, be attributable to
the larger sample size (195 vs 40 patients), the more
extensive cognitive test battery, and the recruitment of
patients with a longer disease duration (mean 5·5 vs
3·5 years) than in our former study. Our study was not a
randomised trial. Thus, selection bias could have
influenced the results. However, we believe that because
patients were recruited from several hospitals with
different therapeutic policies, the risk of such a selection
bias was small.
Our results are in accord with data from preclinical
and clinical studies that have shown that, apart from
radiotherapy variables such as overall dose and
treatment volume, the size of the fraction dose is largely
responsible for the development of late neurotoxicity.11
These findings suggest that radiotherapy given in daily
fractions exceeding 2 Gy is harmful for the normal
surrounding brain over time, rather than conventional
external beam radiotherapy itself. This notion is
supported by Corn and colleagues,27 who reported a
strong relation between radiotherapy fraction size and
risk of late central nervous system injury, and
particularly radiation necrosis. The association between
clinical and neuroimaging features of late radiation
injury (ie, cerebral atrophy and diffuse white matter
disease), which has only partly been elucidated, is the
subject of a separate paper.28
Although, as expected, patients with a tumour in the
dominant hemisphere had more cognitive disability than
those with a non-dominant hemisphere tumour,
cognitive deficits, if present, were not restricted to
specific cognitive domains. This finding is in accord with
reports that glioma patients tend to have global cognitive
deficits rather than the site-specific deficits seen in stroke
patients.29
We saw a somewhat stronger relation between
objective test results and self-reported cognitive function
than that noted in earlier studies of patients with brain
tumours and those with systemic cancer.25,30 Cull and
colleagues17 suggested that cognitive complaints of
cancer patients might actually indicate feelings of
anxiety, depression, or fatigue. Moreover, a dissociation
between objective cognitive test results and self-reported
cognitive function holds true especially for patients with
brain cancer whose judgment could be severely impaired
by the tumour.30
The differences in cognitive function noted between
glioma patients and NHL/CLL patients are more
prominent than those between glioma patients who
received radiotherapy and those who did not. This
finding suggests that the disease itself often results in
poor cognitive function. Because most investigations of
cognitive function in long-term survivors of brain
tumours do not include pretreatment tests of cognition
(which is also true of this study), there is a risk that too
much of the cognitive disability will be ascribed to the
treatment rather than to the tumour. Patients with
haematological cancers also seem to have reduced
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Radiotherapy was not associated with reduced levels of
self-reported cognitive function, whereas longer disease
duration was. In the LGG/RT+ group, an increased total
radiotherapy dose was associated with a diminished
working memory capacity, whereas a high fraction dose
interfered with long-term memory storage and retrieval,
as shown by deficient scores on five of eight memory
tests. Additionally, patients who received large fraction
doses did poorly in  two of 11 tests in the domain of
attention and executive functioning. Only ten patients
received whole-brain radiotherapy with or without boost,
therefore we could not assess the differential effect of
whole-brain versus focal radiotherapy.
Patients on antiepileptics did poorly in two of seven
tests in the domain of perception and psychomotor speed
and in four of 11 tests of attention and executive
function. Use of these drugs was also associated with
reduced self-reported cognitive function. Right
hemisphere lesions were associated with reduced ability
in one of seven tests in the domain of perception and
psychomotor speed, whereas left hemisphere lesions were
associated with deficient scores in five of 11 tests of
attention and executive function. Patients with a tumour
in the left hemisphere had a higher total number of
deviant test scores than those with right-hemisphere
tumours. Biopsy, as opposed to resection, was negatively
associated with memory function as shown by diminished
ability in four of eight memory tests. 
Logistic regression based on the conservative cognitive
criteria (described in the methods) showed that the use of
radiotherapy per se was not associated with cognitive
disability. Increased disease duration was associated with
a slightly increased risk of disability in attention and
executive function (table 3). Although the linear
regression analyses showed that radiotherapy—alone or
in combination with lengthened duration of disease—was
associated with reduced cognitive function, high total
radiotherapy doses were not related to increased risk of
disability in any cognitive domains. However, high
fraction doses were associated with disability in nearly all
memory-related outcome measures, ranging from a six-
fold raised risk for the maximum amount of information
stored in long-term memory to an almost 16-fold
increased risk in learning capacity (Delta score). Data
from post-hoc analyses with correction for differences in
age, sex, education, and disease duration showed that
cognitive disability was mainly present in patients who
received fraction doses exceeding 2 Gy. These 
18 patients (who had fraction doses of 2·1–3·0 Gy)
constituted 17% of all irradiated patients, and were
significantly older than patients who received fraction
doses equal to or lower than 2 Gy (mean 47·5 vs 41·5
years; p=0·028). They did not, however, differ
significantly in tumour localisation or in disease duration.
Antiepileptics were associated with a six-fold increased
risk of disability in psychomotor speed underlying
perceptual tasks, and in the domain of attention and
executive function. Right hemisphere lesions were
associated with a two-fold increase in risk of disability in
the domain of perception and psychomotor speed,
whereas patients with left hemisphere lesions had a two-
fold to 35-fold raised risk of disability in attentional
function. The type of neurosurgical intervention was not
associated with an increased risk of cognitive disability. 
Discussion
We have shown that both irradiated and non-irradiated
low-grade glioma patients have significantly poorer
cognitive functioning than do NHL/CLL patients and,
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cognitive function, as we have shown by the differences
between the group of such patients without central
nervous system involvement and  healthy controls.
Obviously, the possibility of tumour recurrence presents
a psychological burden with resultant anxiety,
depression, or fatigue, which can negatively affect the
patient’s cognitive function.17 The long-term cognitive
impairment in patients with low-grade gliomas is similar
to that seen in patients with mild-to-moderate traumatic
brain injury.31 When cognitive function is compromised
because of the tumour or treatment, physical, social, and
attitudinal factors will affect the patient’s ability to
compensate for these cognitive limitations.
Apart from the tumour itself and the relatively minor
effect of radiotherapy, other medical treatments seem to
affect cognitive function negatively. In our study, the use
of antiepileptics was equally frequent among irradiated
and non-irradiated glioma patients, and patients on
antiepileptics had poorer objectively measured and self-
reported cognitive function than did those without such
treatment. Since 85% of glioma patients in our study
reported seizures, we focused on the use of antiepileptics
as a potential source of variation in cognitive function.
The issue of whether the association seen between use of
antiepileptics and cognitive disability relates to the effect
of the medication or to the underlying epilepsy merits
further attention.
Patients who had a biopsy had poorer cognitive
function than patients who underwent a resection. This
unexpected finding was not due to a high frequency of
biopsies in patients with dominant hemisphere tumours:
42% of such patients underwent biopsy versus 41% of
patients with non-dominant hemisphere tumours.
Possibly the explanation for this difference in cognitive
deficits is that biopsy was the preferred method for large
or deeply located tumours. Perioperative injuries
(records of which could not be reliably retrieved from
the medical charts) were unlikely to be a major risk
factor for cognitive deficits in this group, since if they
had been responsible, we would have expected patients
who underwent resection to have more serious
reductions in cognitive functioning than patients who
had a biopsy.
Our results suggest that the tumour is the main cause
of cognitive deficits, although low-grade glioma patients
treated with early radiotherapy did less well in some
cognitive tests than did low-grade glioma patients who
had no radiotherapy. The main variable responsible for
this difference is the fraction dose size. This observation
has implications for the decision to treat low-grade
glioma with radiotherapy. Since early radiotherapy in
low-grade glioma does not enhance survival, and,
moreover, could contribute to cognitive deficits, early
radiation should not be applied in patients younger than
40 years who have epilepsy. If radiation is applied, either
as an initial treatment or at a later stage, fraction doses
should not exceed 2 Gy. Because the cognitive
disturbances in low-grade glioma patients are mainly
affected by the tumour itself, and, possibly, by
antiepileptic drugs, these factors deserve more attention
than they have previously received.
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